Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review

IF 1.6 Q3 UROLOGY & NEPHROLOGY
BJUI compass Pub Date : 2024-04-24 DOI:10.1002/bco2.365
Hugo Klempfner, Paul Anderson
{"title":"Comparison of staging MRI to re-resection for localised bladder cancer: Narrative review","authors":"Hugo Klempfner,&nbsp;Paul Anderson","doi":"10.1002/bco2.365","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Bladder cancer (BCa) is characterised by high prevalence, multifocality, and frequent recurrence, imposing significant clinical and economic burdens. Accurate staging, particularly distinguishing non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC) disease, is crucial for guiding treatment decisions. This narrative review explores the potential implications of incorporating multiparametric magnetic resonance imaging (mpMRI) and the Vesical Imaging Reporting Data System (VI-RADS) into BCa staging, focusing on repeat transurethral resection of bladder tumour (re-TURBT).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A comprehensive search of PubMed, EMBASE, and MEDLINE databases identified studies published from 2018 to 2023 discussing mpMRI or VI-RADS in the context of re-TURBT for BCa staging. Studies meeting inclusion criteria underwent qualitative analysis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Six recent studies met inclusion criteria. VI-RADS scoring, accurately predicted muscle invasion, aiding in NMIBC/MIBC differentiation. VI-RADS scores of ≥3 indicated MIBC with high sensitivity and specificity. VI-RADS potentially identified patients benefiting from re-TURBT and those for whom it could be safely omitted.</p>\n </section>\n \n <section>\n \n <h3> Discussion</h3>\n \n <p>mpMRI and VI-RADS offer promising prospects for BCa staging, potentially correlating more closely with re-TURBT and radical cystectomy histopathology than initial TURBT. However, validation and careful evaluation of clinical integration are needed. Future research should refine patient selection and optimise mpMRI's role in BCa management.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>VI-RADS scoring could revolutionise BCa staging, especially regarding re-TURBT. There is potential that VI-RADS correlates more with the histopathology of re-TURBT and radical cystectomy than initial TURBT. While promising, ongoing research is essential to validate utility, refine selection criteria, and address economic considerations. Integration of VI-RADS into BCa staging holds potential benefits for patients and health care systems.</p>\n </section>\n </div>","PeriodicalId":72420,"journal":{"name":"BJUI compass","volume":"5 7","pages":"651-661"},"PeriodicalIF":1.6000,"publicationDate":"2024-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/bco2.365","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJUI compass","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/bco2.365","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Bladder cancer (BCa) is characterised by high prevalence, multifocality, and frequent recurrence, imposing significant clinical and economic burdens. Accurate staging, particularly distinguishing non-muscle-invasive bladder cancer (NMIBC) from muscle-invasive bladder cancer (MIBC) disease, is crucial for guiding treatment decisions. This narrative review explores the potential implications of incorporating multiparametric magnetic resonance imaging (mpMRI) and the Vesical Imaging Reporting Data System (VI-RADS) into BCa staging, focusing on repeat transurethral resection of bladder tumour (re-TURBT).

Methods

A comprehensive search of PubMed, EMBASE, and MEDLINE databases identified studies published from 2018 to 2023 discussing mpMRI or VI-RADS in the context of re-TURBT for BCa staging. Studies meeting inclusion criteria underwent qualitative analysis.

Results

Six recent studies met inclusion criteria. VI-RADS scoring, accurately predicted muscle invasion, aiding in NMIBC/MIBC differentiation. VI-RADS scores of ≥3 indicated MIBC with high sensitivity and specificity. VI-RADS potentially identified patients benefiting from re-TURBT and those for whom it could be safely omitted.

Discussion

mpMRI and VI-RADS offer promising prospects for BCa staging, potentially correlating more closely with re-TURBT and radical cystectomy histopathology than initial TURBT. However, validation and careful evaluation of clinical integration are needed. Future research should refine patient selection and optimise mpMRI's role in BCa management.

Conclusion

VI-RADS scoring could revolutionise BCa staging, especially regarding re-TURBT. There is potential that VI-RADS correlates more with the histopathology of re-TURBT and radical cystectomy than initial TURBT. While promising, ongoing research is essential to validate utility, refine selection criteria, and address economic considerations. Integration of VI-RADS into BCa staging holds potential benefits for patients and health care systems.

Abstract Image

局部膀胱癌分期磁共振成像与再次切除术的比较:叙述性综述
摘要膀胱癌(BCa)具有发病率高、多发性和复发频繁的特点,给临床和经济造成了巨大负担。准确的分期,尤其是区分非肌层浸润性膀胱癌(NMIBC)和肌层浸润性膀胱癌(MIBC)疾病,对于指导治疗决策至关重要。本叙述性综述探讨了将多参数磁共振成像(mpMRI)和膀胱成像报告数据系统(VI-RADS)纳入膀胱癌分期的潜在影响,重点关注重复经尿道膀胱肿瘤切除术(re-TURBT)。对PubMed、EMBASE和MEDLINE数据库进行了全面检索,发现了2018年至2023年发表的在膀胱癌分期的re-TURBT背景下讨论mpMRI或VI-RADS的研究。符合纳入标准的研究进行了定性分析。VI-RADS评分能准确预测肌肉侵犯情况,有助于区分NMIBC/MIBC。VI-RADS评分≥3分表示MIBC,具有较高的灵敏度和特异性。mpMRI和VI-RADS为BCa分期提供了广阔的前景,与初次TURBT相比,它们与再次TURBT和根治性膀胱切除术组织病理学的相关性更强。不过,还需要对临床整合进行验证和仔细评估。未来的研究应完善患者选择,优化 mpMRI 在 BCa 管理中的作用。VI-RADS 评分可彻底改变 BCa 分期,尤其是在再次 TURBT 方面。与初次TURBT相比,VI-RADS有可能与再次TURBT和根治性膀胱切除术的组织病理学更相关。尽管VI-RADS前景广阔,但持续的研究对于验证其实用性、完善选择标准和解决经济问题至关重要。将VI-RADS纳入BCa分期可为患者和医疗系统带来潜在的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.30
自引率
0.00%
发文量
0
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信